Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...

(1) The total number of outstanding shares of the Company on 24 January 2025 mentioned in the relevant transparency notifications amounts to 52,416,601, each share giving right to one (1) vote (being ...

Transparency Notifications from Shareholders Ghent, Belgium - 3 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of ...

The morbidity and mortality of hepatic fibrosis caused by various etiologies are high worldwide, and the trend is increasing annually. At present, there is no effective method to cure hepatic fibrosis ...

Polyuria is usually a symptom of other illnesses. Common causes include diabetes, kidney disease, and certain medications. Pregnancy, an electrolyte imbalance, excess caffeine, and drinking alcohol ...